AJP - Renal Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 289: F496-F503, 2005; doi:10.1152/ajprenal.00350.2004
0363-6127/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Imig, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imig, J. D.

INVITED REVIEW

Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases

John D. Imig

Vascular Biology Center, Department of Physiology, Medical College of Georgia, Augusta, Georgia

Renal epoxygenase metabolites are involved in blood flow regulation and long-term blood pressure control. One feature of renal and cardiovascular diseases is the inability of the kidney to properly increase epoxyeicosatrienoic acid (EET) levels. Others (Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, and Weston AH. Trends Phamacol Sci 23: 374–380, 2002; Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Circ Res 78: 415–423, 1996; Capdevila JH and Falck JR. Biochem Biophys Res Commun 285: 571–576, 2001; Roman RJ. Physiol Rev 82: 131–185, 2002; Zeldin DC. J Biol Chem 276: 36059–36062, 2001) and we (Imig JD, Falck JR, Wei S, and Capdevila JH. J Vasc Res 38: 247–255, 2001; Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD. Hypertension 39: 690–694, 2002; Zhao X, Pollock DM, Inscho EW, Zeldin DC, and Imig JD. Hypertension 41: 709–714, 2003; Zhao X, Pollock DM, Zeldin DC, and Imig JD. Hypertension 42: 775–780, 2003) have provided compelling evidence that cytochrome P-450-derived EETs have antihypertensive properties and are endothelially derived hyperpolarizing factors (EDHFs) in the kidney. EETs also possess anti-inflammatory actions that could protect the kidney vasculature from injury during renal and cardiovascular diseases. A tactic that has been used to increase EET levels has been inhibition of the soluble epoxide hydrolase enzyme. Epoxide hydrolase inhibitors have been demonstrated to be antihypertensive and renal protective. Thus the renal and cardiovascular protective actions of increasing epoxygenase levels could be translated to therapies for preventing end-organ damage.

epoxyeicosatrienoic acids; endothelium-derived hyperpolarizing factor; hypertension; nephropathy; inflammation



Address for reprint requests and other correspondence: J. D. Imig, Vascular Biology Ctr., Medical College of Georgia, Augusta, GA 30912-2500 (e-mail: jdimig{at}mail.mcg.edu)




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
H. Jiang, A. G. Zhu, M. Mamczur, C. Morisseau, B. D. Hammock, J. R. Falck, and J. C. McGiff
Hydrolysis of cis- and trans-Epoxyeicosatrienoic Acids by Rat Red Blood Cells
J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 330 - 337.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
G. J. Gross, K. M. Gauthier, J. Moore, J. R. Falck, B. D. Hammock, W. B. Campbell, and K. Nithipatikom
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2838 - H2844.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Q. Ke, Y.-F. Xiao, J. A. Bradbury, J. P. Graves, L. M. DeGraff, J. M. Seubert, and D. C. Zeldin
Electrophysiological Properties of Cardiomyocytes Isolated from CYP2J2 Transgenic Mice
Mol. Pharmacol., October 1, 2007; 72(4): 1063 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. M. Fitzgerald, H. Bashari, J. A. Cox, H. C. Parkington, and R. G. Evans
Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo
Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1072 - H1082.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. Huang, C. Morisseau, J. Wang, T. Yang, J. R. Falck, B. D. Hammock, and M.-H. Wang
Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F342 - F349.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. A. Spector and A. W. Norris
Action of epoxyeicosatrienoic acids on cellular function
Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. A. Elmarakby, J. E. Quigley, D. M. Pollock, and J. D. Imig
Tumor Necrosis Factor {alpha} Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension
Hypertension, March 1, 2006; 47(3): 557 - 562.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.